Skip to main content
Clinical Trials/EUCTR2007-006117-16-GB
EUCTR2007-006117-16-GB
Active, not recruiting
Phase 1

A prospective, randomised, phase IV, open label clinical trial to study the therapeutic use of buprenorphine 20 mg (BuTrans 20µg/h) matrix transdermal patch in the management of post tonsillectomy pain in adults - PATCH Trial

Betsi Cadwaladr University Health Board0 sites300 target enrollmentNovember 26, 2007

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Betsi Cadwaladr University Health Board
Enrollment
300
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 26, 2007
End Date
February 15, 2012
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing tonsillectomy, which meet the following criteria:
  • aged 18 to 50 years old;
  • ASA grade I \& II \- healthy patient; mild systemic disease with no functional limitation (e.g. well controlled HTA)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • age less than 18 or over 50;
  • ASA grade III \- severe systemic disease with definite functional limitation e.g. unstable angina)
  • conditions in which the respiratory centre and function are severely impaired or may become so;
  • asthmatic and allergic to NSAIDS;
  • hypotension
  • pregnancy and lactation;
  • recent head injury;
  • known hypersensitivity towards the active substance buprenorphine or to any of the excipients (for the excipients see section 6\.1\);
  • in opioid\-dependent patients and for narcotic withdrawal treatment;
  • patients who are receiving MAO inhibitors or have taken them within the last two weeks;

Outcomes

Primary Outcomes

Not specified

Similar Trials